Universidad Peruana Cayetano Heredia

Efficacy of three different regimens of primaquine for the prevention of relapses of Plasmodium vivax malaria in the Amazon Basin of Peru

Mostrar el registro sencillo del ítem

dc.contributor.author Durand, Salomón
dc.contributor.author Cabezas, Cesar
dc.contributor.author Lescano Guevara, Andres Guillermo
dc.contributor.author Galvez, Mariela
dc.contributor.author Gutierrez, Sonia
dc.contributor.author Arrospide, Nancy
dc.contributor.author Alvarez, Carlos
dc.contributor.author Santolalla Robles, Meddly Leslye
dc.contributor.author Bacon, David J.
dc.contributor.author Graf, Paul C. F.
dc.date.accessioned 2020-06-10T18:11:30Z
dc.date.available 2020-06-10T18:11:30Z
dc.date.issued 2014
dc.identifier.uri https://hdl.handle.net/20.500.12866/7961
dc.description.abstract We evaluated the efficacy of three primaquine (PQ) regimes to prevent relapses with Plasmodium vivax through an open-label randomized trial in Loreto, Peru. Vivax monoinfections were treated with chloroquine for 3 days and PQ in three different regimes: 0.5 mg/kg per day for 5 days (150 mg total), 0.5 mg/kg per day for 7 days (210 mg total), or 0.25 mg/kg per day for 14 days (210 mg total). Biweekly fever assessments and bimonthly thick smears were taken for 210 days. Recurrences after 35 days were considered relapses. One hundred eighty cases were enrolled in each group; 90% of cases completed follow-up. There were no group-related differences in age, sex, or parasitemia. Relapse rates were similar in the 7- and 14-day regimes (16/156 = 10.3% and 22/162 = 13.6%, P = 0.361) and higher in the 5-day group (48/169 = 28.4%, P < 0.001 and P = 0.001, respectively). The 7-day PQ regimen used in Peru is as efficacious as the recommended 14-day regimen and superior to 5 treatment days. en_US
dc.language.iso eng
dc.publisher American Society of Tropical Medicine and Hygiene
dc.relation.ispartofseries American Journal of Tropical Medicine and Hygiene (ASTMH Journal)
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Adolescent en_US
dc.subject Adult en_US
dc.subject Aged en_US
dc.subject Antimalarials/pharmacology en_US
dc.subject Child en_US
dc.subject Child, Preschool en_US
dc.subject Chloroquine/pharmacology en_US
dc.subject Drug Administration Schedule en_US
dc.subject Drug Therapy, Combination en_US
dc.subject Female en_US
dc.subject Humans en_US
dc.subject Malaria, Vivax/drug therapy/parasitology en_US
dc.subject Male en_US
dc.subject Middle Aged en_US
dc.subject Peru en_US
dc.subject Plasmodium vivax/physiology en_US
dc.subject Primaquine/pharmacology en_US
dc.subject Recurrence en_US
dc.subject Treatment Outcome en_US
dc.title Efficacy of three different regimens of primaquine for the prevention of relapses of Plasmodium vivax malaria in the Amazon Basin of Peru en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.4269/ajtmh.13-0053
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.06
dc.relation.issn 1476-1645


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas